ResMed, Inspire Medical Shares Down After Eli Lilly Provides Sleep Apnea Study Update
By Josh Beckerman
Shares of ResMed, a breathing technology company, fell after Eli Lilly said its weight-loss drug tirzepatide reduced the severity of sleep apnea in Phase 3 trials.
RedMed's shares dropped the most in 10 months on Monday, retreating 11% to $182.73 in early afternoon trading. The stock has declined 15% in the last 52 weeks.
Citi downgraded breathing technology company ResMed to neutral from buy on Monday.
Needham said in a research note that Lilly's results were in line with its expectations. "Given the relatively modest near-term headwind we expect through FY27, we view today's weakness as a buying opportunity" for ResMed shares.
Meanwhile, shares of Inspire Medical Systems, which provides technology for sleep apnea, were down 15% to $138.17. Stifel Financial reduced its target price for Inspire to $170 from $210 and maintained its hold rating.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 24, 2024 13:43 ET (17:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
What’s Happening In the Markets This Week
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What a Strong Economy Now Means for the Rest of 2024
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks